The patientwho had come to Wuhan from far away hoping to receive a kidney transplantexperienced a huge shock, but fortunately he did recover from COVID-19

The patientwho had come to Wuhan from far away hoping to receive a kidney transplantexperienced a huge shock, but fortunately he did recover from COVID-19. IgG titer, Kidney transplantation 1.?Introduction As of May 14, more than four million people have confirmed coronavirus disease 2019 (COVID-19) and more than 290,000 patients have died [1]. Patients with end-stage renal disease (ESRD) are susceptible to infection with the virus that causes COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to frequent hospital visitation for hemodialysis, and their reduced immunity status[2]. Many ESRD patients have reportedly been infected with SARS-CoV-2 in Wuhan [3,4]. Most have recovered well. Because of the transmissibility of the SARS-CoV-2, these patients must not receive a kidney transplant while they have pneumonia [5]. There are also questions about whether it is safe for them to receive a kidney HDAC-IN-7 transplant after recovery from COVID-19. There are concerns that immunosuppressants could lead to replication of underlying virus, leading to COVID-19 recurrence after the transplant. Whether different immunosuppression regimens and/or COVID-19 infection prevention measures are required in these patients Mouse monoclonal to CD45 to enable them to receive kidney transplants is unknown. Currently scant data are available on the management of patients who have received a kidney transplant after recovery from COVID-19. Herein we report the first case of kidney transplantation in a patient who had recently recovered from COVID-19. 2.?Case A 38-year-old man with ESRD was admitted into our hospital for kidney transplant evaluation on 15 December 2020. His medical history indicated that urinary protein had been discovered in a routine physical examination in 2012, but his serum creatinine level was normal. Renal biopsy suggested hepatitis B-related glomerulonephritis, and oral medication was used to control the progression of chronic kidney disease. In 2015 his renal function deteriorated and serum creatinine increased to 150?mol/L. Regular hemodialysis treatment began in June 2016. Other aspects of his medical history included hypertension for 3?years, psoriasis for 1?yr, and hepatitis B for many years. Considerable laboratory checks and imaging were performed to evaluate the function of various organs, as were iliac vascular screening and cells coordinating checks. There was no contraindication for any kidney transplant, so the patient’s HDAC-IN-7 info was entered into the China Organ Transplant Registration System. He had rented a house in Wuhan and was receiving hemodialysis regularly, while waiting for a kidney transplant. Regrettably, he developed a fever, coughing, and analgia from 25 January 2020. Test results included white blood cells 2.6??10 9/L, lymphocytes 0.43??10 9/L, and C-reactive protein 6?mg/L. Chest computed tomography (CT) on 26 January 2020 depicted one patchy shadow in the right lung near the pleura. PCR screening was then performed using nose and throat swabs, but it was bad for SARS-CoV-2. From that day time onward the patient was treated with oseltamivir and moxifloxacin, HDAC-IN-7 but his symptoms worsened, including fever (38.9?C), sore throat, coughing, and sputum production. On 29 January 2020 he underwent chest CT again, and it depicted quick progression of the previously observed lesion with multiple patchy ground-glass denseness shadows in the right lung near the pleura. This time nose and throat swab PCR checks for SARS-CoV-2 were positive, therefore he was analysis with COVID-19 and transferred to the isolation ward [6]. Arbidol (200?mg three times each day orally), ganciclovir (200?mg two times each day), and immunoglobulin (10?g daily) were administered as antiviral drugs. Continuous renal alternative therapy was given every 2?days to replace regular hemodialysis. His respiratory symptoms gradually worsened and oxygen HDAC-IN-7 therapy was contemplated. Chest CT on 06 February 2020 revealed development of the lung lesions with multiple patchy ground-glass denseness shadows in both lungs, but at this point SARS-CoV-2 PCR checks were bad. Since that timepoint his respiratory symptoms gradually improved, multiple CT scans indicated the lesion was gradually becoming soaked up, and multiple SARS-CoV-2 PCR checks were bad. On 21 February 2020 SARS-CoV-2 antibody screening indicated an IgM titer of 392?AU/mL and an IgG titer of 76?AU/mL. After a long period of treatment the patient recovered, and he was discharged from the hospital on 28 February 2020 and recommenced regular hemodialysis. Multiple subsequent CT examinations indicated the lesions were slowly soaked up. Multiple subsequent SARS-CoV-2 PCR checks carried out at multiple sites were all bad, and serum SARS-CoV-2 IgG remained positive and serum IgM gradually disappeared (Fig. 1 ). Open in a separate windowpane Fig. 1 Timeline of medical characteristics of the current end-stage renal disease patient.